Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis

M. Anderson, D. Moore, Douglas F. Larson

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy. Currently, dobutamine (Dob) has replaced Iso as the preferred inotropic β-adrenergic agent to wean patients from cardiopulmonary bypass and to sustain adequate cardiac function during the postoperative period. We sought to compare the cardiac structural and functional effects of long-term administration (7days) of Iso with Dob at a dose of 40μg/ mouse/day in 12-week-old C57BL/6 female mice. Cardiac function was determined with transthoracic echo cardiography (ECHO) 24 hours after the last dose. Cardiac wet weights increased 33% and 24% in the Iso and Dob groups compared with controls (p < 0.05). Dob and Iso significantly increased cardiac fibrosis and decreased cardiac function with chronic administration. Administration also resulted in increased left atrial size, suggesting that both Dob and Iso decreased LV compliance, but did not induce heart failure. In conclusion, chronic administration of Dob may have a detrimental effect on cardiac structure and function.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
Issue number4
StatePublished - 2008
Externally publishedYes


  • Cardiac
  • Echocardiogram
  • Extracellular matrix
  • Fibrosis
  • Remodeling
  • β-adrenergic

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Safety Research
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing


Dive into the research topics of 'Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis'. Together they form a unique fingerprint.

Cite this